Studying the effect of almond on Alzheimer's disease

Early Phase 1

Conditions: Alzheimer.
Dementia in Alzheimer disease
F00.1

Registration Number: IRCT20231031059912N1

Lead Sponsor: Vice Chancellor for Research & Technology

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 60

Inclusion Criteria

Patients diagnosed based on history and questionnaire and examination and paraclinic under the supervision of psychiatrist or neurologist or geriatrics specialist
Having no other psychiatric disease causing dementia other than Alzheimer's based on the opinion of a specialist
Not having severe non-psychiatric and non-neurological diseases based on the opinion of a specialist
Not abusing substances or drugs (except nicotine and caffeine) such as narcotics or stimulants
Informed written consent of the patient or the patient's guardian to enter the plan

Exclusion Criteria

Uncontrolled diabetes mellitus because the almonds are slightly sweetened with candy

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in score of MMSE and FAST questionnaires, CDR and MoCA and sleep questionnaire. Timepoint: Completing the questionnaire at the beginning of the study (before the start of the intervention) and 3 months after starting to consume almonds. Method of measurement: MMSE? MoCA? CDR? FAST and sleep questionnaires.

Secondary Outcome Measures

Name	Time	Method
Complications. Timepoint: The time periods of completing the questionnaire as a secondary outcome, at the beginning of the study (before the start of the intervention) and 3 months after consuming almonds. Method of measurement: MMSE and FAST, CDR and MoCA and sleep questionnaires.